NBC News reports:
The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer.
The test isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States.
Shield has previously been available to doctors as a screening tool, at an out-of-pocket cost of $895. With the FDA approval, Medicare and private insurance companies are much more likely to cover the cost of the blood test, making it more widely accessible for patients.
Read the full article.
The US Food and Drug Administration has approved a blood test to be used for colorectal cancer screening among average-risk adults 45 and older. https://t.co/PLEJcDrc33
— KWWL (@KWWL) July 29, 2024